GEVORGYAN, ARPINE
GEVORGYAN, ARPINE
Universita' degli Studi di MILANO
Body mass index and clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer
2016 A. Gevorgyan, G. Bregni, G. Galli, M. Ganzinelli, A. Martinetti, S.L. Vullo, L. Mariani, F. Festinese, E. Sottotetti, F. De Braud, S. Di Cosimo
HER2-Positive Neuroendocrine Breast Cancer: Case Report and Review of Literature
2016 A. Gevorgyan, G. Bregni, G. Galli, E. Zanardi, F. De Braud, S. Di Cosimo
Trastuzumab cardiac toxicity : A problem we put our heart into
2016 G. Bregni, G. Galli, A. Gevorgyan, F. De Braud, S. Di Cosimo
Disease progression pattern in metastatic breast cancer patients treated with anti-HER2 therapies
2015 D. Serpico, L. Porcu, A. Tessari, A. Gevorgyan, G. Bregni, G. Galli, F. de Braud, V. Torri, S. Di Cosimo
Chronomodulated capecitabine and adjuvant radiation in intermediate-risk to high-risk rectal cancer : a phase II study
2014 E. Bajetta, F. Pietrantonio, R. Buzzoni, E. Ferrario, F. Valvo, L. Mariani, K.F. Dotti, P. Biondani, B. Formisano, A. Gevorgyan, P. Grassi, M. Di Bartolomeo
Circulating biomarkers in advanced colorectal cancer patients randomly assigned to three bevacizumab-based regimens
2014 A. Martinetti, R. Miceli, E. Sottotetti, M. Di Bartolomeo, F. de Braud, A. Gevorgyan, K.F. Dotti, E. Bajetta, M. Campiglio, F. Bianchi, G. Bregni, F. Pietrantonio
Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation
2014 F. Pietrantonio, F. Perrone, F. De Braud, A. Castano, C. Maggi, I. Bossi, A. Gevorgyan, P. Biondani, M. Pacifici, A. Busico, M. Gariboldi, F. Festinese, E. Tamborini, M. Di Bartolomeo
Role of the antiangiogenic agent bevacizumab in the treatment of elderly patients with metastatic colorectal cancer
2011 M. Di Bartolomeo, F. Pietrantonio, A. Martinetti, R. Buzzoni, A. Gevorgyan, E. Bajetta